David Baldinger, MD
Rheumatology · Fort Myers, FLNPI 1144228362
Payments from drug & device makers
Across 1,017 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$5K
- Mallinckrodt Hospital Products Inc.$2K
- AbbVie$2K
- UCB, Inc.$2K
- Johnson & Johnson$1K
- Pfizer$916
- plus $6K from 31 others
What the payments were for
- Food & beverage$19,642100%
- Education$540%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 294 | $5,398 |
| Mallinckrodt Hospital Products Inc. | 104 | $2,384 |
| AbbVie | 115 | $2,147 |
| UCB, Inc. | 108 | $1,717 |
| Johnson & Johnson(2 entities) | 66 | $1,420 |
| Pfizer | 50 | $916 |
| Boehringer Ingelheim | 26 | $668 |
| Lilly USA, LLC | 34 | $610 |
| AstraZeneca(2 entities) | 24 | $547 |
| GSK | 34 | $542 |
| Radius Health, Inc. | 26 | $527 |
| E.r. Squibb & Sons, L.L.C. | 23 | $483 |
| Sanofi | 18 | $445 |
| Aurinia Pharma U.S., Inc. | 10 | $236 |
| ANI Pharmaceuticals, Inc. | 11 | $226 |
| Novartis | 11 | $185 |
| Mallinckrodt Enterprises LLC | 8 | $176 |
| Actelion Pharmaceuticals US, Inc. | 10 | $159 |
| Scilex Pharmaceuticals Inc. | 6 | $123 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $91 |
| Genentech USA, Inc. | 5 | $85 |
| Kyowa Kirin, Inc. | 3 | $72 |
| Sobi, Inc | 4 | $70 |
| Fresenius Kabi USA, LLC | 3 | $70 |
| Ultragenyx Pharmaceutical Inc. | 2 | $48 |
| Collegium Pharmaceutical, Inc. | 2 | $48 |
| Almatica Pharma LLC | 3 | $48 |
| Sandoz | 2 | $38 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $37 |
| Organon | 2 | $34 |
| Antares Pharma, Inc. | 2 | $28 |
| Bristol Myers Squibb | 1 | $23 |
| Biocon Biologics Inc | 1 | $22 |
| Harmony Biosciences LLC | 1 | $19 |
| Orthogenrx Inc. | 1 | $19 |
| Cumberland Pharmaceuticals, Inc. | 1 | $18 |
| Fidia Pharma USA Inc. | 1 | $15 |
How this compares
$19,696 in reported general payments places this provider in the 60th percentile of 453 rheumatology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 108 | $836,906 |
| Humira(Cf) PenAdalimumab | 99 | $797,806 |
| Enbrel MiniEtanercept | 51 | $412,821 |
| RinvoqUpadacitinib | 29 | $214,380 |
| OtezlaApremilast | 40 | $198,836 |
| Cimzia (2 Pack)Certolizumab Pegol | 30 | $186,203 |
| EnbrelEtanercept | 25 | $182,556 |
| Xeljanz XrTofacitinib Citrate | 24 | $179,891 |
| Orencia ClickjectAbatacept | 27 | $169,086 |
| Taltz AutoinjectorIxekizumab | 16 | $113,183 |
| XeljanzTofacitinib Citrate | 16 | $107,465 |
| ActemraTocilizumab | 14 | $93,156 |
| Humira PenAdalimumab | 13 | $86,709 |
| KevzaraSarilumab | 20 | $84,134 |
| Actemra ActpenTocilizumab | 14 | $37,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla, Enbrel | $5,398 | $381,39265 claims |
| AbbVieRinvoq, Savella | $2,147 | $224,47550 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,717 | $186,20330 claims |
| PfizerXeljanz | $916 | $107,46516 claims |
| SanofiKevzara | $445 | $84,13420 claims |
| Collegium Pharmaceutical, Inc.Nucynta Er | $48 | $21,72911 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $123 | $1,52728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 453 rheumatology providers in Florida.
Other rheumatology in Fort Myers
- Martha Hernandez IllasFort Lauderdale$25M
- Carlos SesinMiami Beach$19M
- Guillermo ValenzuelaPlantation$14.2M
- Marimer Rensoli VelazquezMiami$12.2M
- Robert LevinClearwater$11M
- Jigar ShahMargate$5.6M
- Michael BubbGainesville$3.3M
- Vipul JoshiBrandon$3.1M
- Alvin WellsDestin$2.9M
- Benidecto FernandezHialeah$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.